[1] Agirre, X. et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res 6, 1830-1840, doi:10.1158/1541-7786.MCR-08-0167 (2008).
[2] Garzon, R. et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183-3189, doi:10.1182/blood-2007-07-098749 (2008).
[3] Dixon-McIver, A. et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3, e2141, doi:10.1371/journal.pone.0002141 (2008).
[4] Falini, B. et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 23, 1731-1743, doi:10.1038/leu.2009.124 (2009).
[5] Meani, N. & Alcalay, M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther 9, 1283-1294, doi:10.1586/era.09.84 (2009).
[6] Zhang, Y., Zhang, M., Yang, L. & Xiao, Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 31, 109-111, doi:10.1016/j.leukres.2006.03.013 (2007).
[7] Piccaluga, P. P. et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia 23, 1370-1371, doi:10.1038/leu.2009.95 (2009).
[8] Cheng, K. et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 26, 7391-7400, doi:10.1038/sj.onc.1210549 (2007).
[9] den Besten, W., Kuo, M. L., Williams, R. T. & Sherr, C. J. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4, 1593-1598, doi:10.4161/cc.4.11.2174 (2005).
[10] Falini, B., Nicoletti, I., Martelli, M. F. & Mecucci, C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109, 874-885, doi:10.1182/blood-2006-07-012252 (2007).
[11] Zheng, H., Liu, J. Y., Song, F. J. & Chen, K. X. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med 10, 123-130, doi:10.7497/j.issn.2095-3941.2013.03.001 (2013).
[12] Summerer, I. et al. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol 8, 296, doi:10.1186/1748-717X-8-296 (2013).
[13] Visone, R. & Croce, C. M. MiRNAs and cancer. Am J Pathol 174, 1131-1138, doi:10.2353/ajpath.2009.080794 (2009).
[14] Zhi, Y. et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol 102, 296-303, doi:10.1007/s12185-015-1829-6 (2015).
[15] Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413, doi:10.1126/science.aan6733 (2017).
[16] Ovcharenko, D. et al. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol 39, 1030-1042 e1037, doi:10.1016/j.exphem.2011.07.008 (2011).
[17] Bryant, A. et al. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer 11, 8, doi:10.1186/1476-4598-11-8 (2012).
[18] Li, Q., Liu, L. & Li, W. Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis. Tumour Biol 35, 10467-10478, doi:10.1007/s13277-014-2364-4 (2014).
[19] Li, C., Gao, Q., Wang, M. & Xin, H. LncRNA SNHG1 contributes to the regulation of acute myeloid leukemia cell growth by modulating miR-489-3p/SOX12/Wnt/beta-catenin signaling. J Cell Physiol, doi:10.1002/jcp.29892 (2020).
[20] Chen, S. et al. Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis. Int J Med Sci 17, 1269-1280, doi:10.7150/ijms.46441 (2020).
[21] He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833, doi:10.1038/nature03552 (2005).
[22] Uziel, T. et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A 106, 2812-2817, doi:10.1073/pnas.0809579106 (2009).
[23] Ohuchida, K. et al. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol 19, 2394-2402, doi:10.1245/s10434-012-2252-3 (2012).
[24] Bosman, M. C. et al. The TAK1-NF-kappaB axis as therapeutic target for AML. Blood 124, 3130-3140, doi:10.1182/blood-2014-04-569780 (2014).
[25] Roussignol, G. et al. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 25, 3560-3570, doi:10.1523/JNEUROSCI.4354-04.2005 (2005).
[26] Guilmatre, A., Huguet, G., Delorme, R. & Bourgeron, T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol 74, 113-122, doi:10.1002/dneu.22128 (2014).